APPENDICURE

Innovations in the Treatment of Appendix Cancer

BLOG

Author: Amanda Moore

  • How a New Cancer Drug Actually Gets Approved

    How a New Cancer Drug Actually Gets Approved

    APPENDICURE  ·  PATIENT EDUCATION And why, for a rare cancer community, every approval somewhere else is a small lesson in what to watch for. If you spend any time in appendix cancer communities, you have probably seen the same pattern. Someone shares a news article about a promising new drug. The headline sounds like a…

  • Right to Try, Compassionate Use, and Early Access: What Appendix Cancer Patients Should Know

    RESEARCH SPOTLIGHT  ·  TREATMENT ACCESS When standard treatment runs out, a handful of legal pathways may open the door to investigational therapies. Here is what they actually are, how they work, and what to ask for. One of the hardest realities of a rare cancer is that promising therapies often exist for years before patients…

  • Why PMP Behaves the Way It Does: A New Look at the Biology of the Disease

    If you live with pseudomyxoma peritonei, or love someone who does, you already know the central strangeness of it. The pathology reports use words like “low grade.” The tumors do not divide quickly. And yet the disease keeps producing mucin, year after year, surgery after surgery, until the abdomen cannot hold any more. This is…

  • Why Some Men With Appendix Cancer Still Aren’t Getting CA125 Testing

    New research is raising an uncomfortable question. Are some appendix cancer patients, especially men, missing an important tumor marker because of an outdated assumption about who it’s for? For years, appendix cancer patients have had their bloodwork monitored with tumor markers like CEA and CA19-9. CA125, historically associated with ovarian cancer, has not always been…

  • What Tumor Markers Tell Us Before and After CRS

    A new MD Anderson study of 376 cytoreductive surgeries finds that CEA, CA19-9, and CA125, considered together and tracked over time, give surgeons and patients meaningful information about disease burden, surgical outcomes, and the years that follow. FROM OUR COMMUNITYMany Appendicure members have watched their CEA, CA19-9, or CA125 numbers shift in the weeks before…

  • What You Need to Know About Stomas in CRS and HIPEC

    If you are heading into CRS and HIPEC for appendix cancer, there is a conversation worth having with your surgical team before the day of surgery, and it is the one most patients tell us they wish they had pushed harder for: the stoma conversation. A retrospective study published this spring in Medical Research Archives…